2009 Canadian Hypertension Education Program recommendations: an annual update. - Wikidata - awgldk - TriplyDB

2009 Canadian Hypertension Education Program recommendations: an annual update.

2009 Canadian Hypertension Education Program recommendations: an annual update.

http://www.wikidata.org/entity/Q37281600

about

Hypertension management by family physicians: is it time to pat ourselves on the back?Give patients free blood pressure home-monitoring kits.A prescription for sodium.Prise en charge de l’hypertension par les médecins de famille: Est-ce le temps de nous féliciter?

P2860

Q37283163-16CEE2CE-FE91-4684-B624-6BAB85D58E95 Q42554842-BF34E0C7-0A0D-4E7A-A15D-19C178028719 Q42634970-B4D34C7A-EC44-44C2-A5C1-DAFFD52D1430 Q55399633-DE7EC9FB-8738-4037-9DA1-50D476584A59

P2860

2009 Canadian Hypertension Education Program recommendations: an annual update.

http://www.wikidata.org/entity/Q37281600

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

2009 Canadian Hypertension Education Program recommendations: an annual update.

@en

2009 Canadian Hypertension Education Program recommendations: an annual update.

@nl

type

label

2009 Canadian Hypertension Education Program recommendations: an annual update.

@en

2009 Canadian Hypertension Education Program recommendations: an annual update.

@nl

prefLabel

2009 Canadian Hypertension Education Program recommendations: an annual update.

@en

2009 Canadian Hypertension Education Program recommendations: an annual update.

@nl

P1433

Q37281600-034F9018-F0DA-4DEF-AF2D-C3C0681588AC

P1476

Q37281600-FFD8853F-3334-41E6-8DB3-5BDA297410EC

P2093

Q37281600-D2EC6F87-8CC5-416D-9A52-C7C412CD7C99

P2860

Q37281600-050E8BBD-1CBF-4AD2-AB63-C8B83D9C85B7

Q37281600-05C8176C-DA04-4BD5-B0DA-E2C0B0F66308

Q37281600-1055E5DE-2227-4A8B-9AB5-0D1F824A3ED3

Q37281600-1306C549-6A76-4CA4-B2AA-F434C0250C76

Q37281600-23F238AB-EB42-4A31-B5C3-5F6588F51227

Q37281600-29AE81C9-8F7A-40F7-B88C-768BE6D48A37

Q37281600-2A5FFF95-948D-4518-9670-9684A48E3D41

Q37281600-2ECDBFBF-0EE5-41C2-AE48-DA9D05575723

Q37281600-486CD435-4BA3-4F0D-A778-A67B8DFAEB9A

Q37281600-55DDE0A2-440D-4029-84E9-B7B4310C271A

P304

Q37281600-F0086226-7EA1-44EA-AE9F-72E20D5CB6B2

P31

Q37281600-B3033351-D70C-4879-96C4-A2599AB60459

P407

Q37281600-0D075147-32DE-4AF6-8D06-E9D17844A63E

P433

Q37281600-8535A651-E718-41C9-BCBA-A5BCD06F06C6

P478

Q37281600-765AEF1C-D691-46E1-8475-3CF8FFA97A92

P577

Q37281600-97E4B297-1773-42BB-845D-AB6802DE1F9D

P698

Q37281600-F37D7B31-8126-4941-9494-39396D43996A

P921

Q37281600-285C170E-E127-4994-A76A-F79F86D80E58

P932

Q37281600-52DF7FC8-AA6E-4162-A903-A8655DB81988

P1433

Canadian Family Physician

P1476

2009 Canadian Hypertension Education Program recommendations: an annual update

@en

P2093

Canadian Hypertension Education Program

http://www.w3.org/2001/XMLSchema#string

P2860

Results of the Ontario survey on the prevalence and control of hypertension

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Diabetes, hypertension, and cardiovascular disease: an update.

Telmisartan to prevent recurrent stroke and cardiovascular events.

P304

697-700

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19602652

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension

P932

2718051

http://www.w3.org/2001/XMLSchema#string